Home » Authors » Jim Shrine

Jim Shrine

Articles

ARTICLES

NIH Initiates Phase III Trial Of Avicena's Creatine Agent for PD

March 23, 2007

NIH Initiates Phase III Trial Of Avicena's Creatine Agent for PD

March 23, 2007

Avexa Raises $60.1M To Fund Phase III Trials Of HIV Agent

March 22, 2007

Australian biotechnology company Avexa Ltd. parlayed positive Phase IIb data on its lead HIV compound into a funding round that will total A$75 million (US$60.1 million). (BioWorld Today)

Avexa Raises $60.1M To Fund Phase III Trials Of HIV Agent

March 22, 2007

Australian biotechnology company Avexa Ltd. parlayed positive Phase IIb data on its lead HIV compound into a funding round that will total A$75 million (US$60.1 million). (BioWorld Today)

Alethia Enters Deal With Biosite For Ovarian Cancer Antibodies

March 14, 2007

Alethia Enters Deal With Biosite For Ovarian Cancer Antibodies

March 14, 2007

Neose Raising $43.3M Through A Placement Of Stock, Warrants

March 12, 2007

Neose Raising $43.3M Through A Placement Of Stock, Warrants

March 12, 2007

Avalon, Merck Collaborate To Work On Difficult Cancer Target

March 8, 2007

Avalon, Merck Collaborate To Work On Difficult Cancer Target

March 8, 2007

View All Articles by Jim Shrine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld Science
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...